Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Prostate Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Prostate Cancer
    Prostate Cancer Patients Disease Free After 5 Years Likely to Be Disease Free After 10 Years - (DGNews)
    Selenium May Worsen Prostate Cancer in Men With SOD2 Gene Variant - (DGNews)
    TopAbstracts in Prostate Cancer 06/24/2009 - (DGNews)
    Prostate Cancer Test Improves Prediction of Disease Course - (DGNews)
    Duration of androgen suppression in the treatment of prostate cancer - (N Engl J Med)

    News archive

     Recent webcasts/CME - Prostate Cancer
    • Exploring the Link Between Hypogonadism and Metabolic Comorbidities
    • Diagnosing Hypogonadism: Recommendations for Testing and Treating to Improve Outcomes
    • Remplacement de la testostérone : surveillance d'un point de vue pratique
    • Finasteride and Prostate Cancer Prevention: The Latest Chapter
      Emerging Research May Improve Prostate Cancer Treatment

      Webcasts/CME archive

       Recent cases - Prostate Cancer
        Non-Prostatic Pathology on Prostate Needle-Biopsy - Colorectal Carcinoid: A Case Report
        A 70-Year-Old Male Having Advanced Prostate Cancer Presenting with Hypercalcemia and Diffuse Osteoblastic Bone Metastases: A Case Report
        A Dramatic, Objective Antiandrogen Withdrawal Response: Case Report and Review of the Literature
        Anejaculation as an Atypical Presentation of Prostate Cancer: A Case Report
        FDG PET-CT Demonstration of Metastatic Neuroendocrine Tumor of Prostate

        Cases archive
          




        my personal edition > prostate cancer > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Radical Prostatectomy Has Role in Management of High-Grade Prostate Cancer: Presented at EAU

        By Jill Stein

        MILAN, Italy -- March 26, 2008 -- Men treated with initial radical prostatectomy (RP) for high-grade prostate cancer have a median survival of nearly 12 years, according to data reported here at the 23rd Annual European Meeting of the Association of Urology (EAU).

        Ryan Terlecki, MD, Chief Administrative Resident, Urology Division, Wayne State University/Karmanos Cancer Center, Detroit, Michigan, and associates reviewed overall survival outcomes in men followed for 10 years after undergoing initial RP for high-grade prostate cancer.

        For their analysis, the investigators queried the Karmanos Cancer Center database for patients treated with initial RP for high-grade prostate cancer.

        Overall, 145 patients were identified from 4 treatment groups: RP alone, RP plus androgen deprivation therapy, RP plus radiation, and RP plus radiation and androgen deprivation therapy.

        The trial excluded patients who had received any form of cancer-directed therapy prior to surgery.

        Mean age at surgery was 64 years, and median survival was 140 months.

        Results showed that only age and African-American race were significant risk factors for worse survival, Dr. Terlecki said in a presentation on March 26.

        In addition, adjuvant therapies beyond RP did not produce a significant survival benefit. "This finding highlights the importance of discretionary use of additional modes of treatment," Dr. Terlecki said.

        The investigator cautioned that the results may be limited by the study's retrospective design. Also, there may have been a selection bias with regard to which patients were selected for surgery. In addition, they did not stratify their results by individual surgeon.

        [Presentation title: Radical Prostatectomy as Monotherapy or as Part of Multimodal Management of High-Grade Prostate Cancer With 10-Year Minimum Follow-Up. Abstract 119]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send